Home prices in China resumed its growth after stalling in February due to the pandemic. The resurgence implies pent-up demand as the effects of the outbreak steadily eased on property markets.
China has recently lifted curfews and lockdowns as authorities slowly brought the COVID-19 pandemic under control.
Average new home prices in 70 of China’s major cities grew by 0.1% in March from the previous month with figures remaining unchanged for February. The data comes from Reuters’ calculation based on Thursday’s report by the National Bureau of Statistics (NBS).
On a year-on-year basis, home prices grew by 5.3% in March after dropping from a 5.8% uptick in February.
Leading property developers including Evergrande has launched discounts and promotions to bolster home sales. This led to property sales soaring 136.2% last month according to data from researcher CRIC based on the nation’s top 100 developers.
Developers said that sales would resume in April as the world’s second-largest economy is expect to make a major recovery in March. However, analysts cautioned consumers over lingering virus fears and possible job losses.
On Friday, the Chinese technology company ByteDance said that it would consider listing its domestic businesses in Hong Kong or Shanghai due to rising Sino-U.S. tensions. The company's standalone listing in Hong Kong or Shanghai might value ...
Oil traded higher on Friday, further reclaiming lost ground from three-week lows in the previous session as the COVID-19 situation continued to dent the global economy as well as oil consumption. Brent crude gained 0.3%, trading at $43.08 ...
Asian shares recorded a turbulent session on Friday as weak economic data from the United States and surging coronavirus infections worldwide dragged market confidence. The decline followed despite upbeat U.S. tech gains and signs of rebound ...
The second quarter had seen Australian consumer prices dropping by a record. This could be attributed to the coronavirus crisis dragging child care cost and petroleum prices, inflicting a serious damage to years of growth toward higher inflation. Last ...
Britain on Wednesday signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine that is being developed by pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi. The financial details of the agreement were not disclosed. However, ...